Cassava Sciences (SAVA) said Monday that its late-stage trial of simufilam in mild-to-moderate Alzheimer's disease did not meet the co-primary endpoints of cognitive and functional improvement.
Secondary and exploratory biomarker endpoints also were not met, the clinical-stage company said, adding that the drug maintained a favorable safety profile despite the trial outcomes.
Shares of the company were down 83% in recent premarket activity.
Price: 4.36, Change: -22.12, Percent Change: -83.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.